The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent B-cell depletion and recovery, as well as improved disease activity, said ...

Serum S100A8/A9 levels are “significantly higher’ among patients with cognitive impairment in systemic lupus erythematosus, and changes in S100A8/A9 correspond to changes in cognition over 1 year, ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in ...

Researchers from EMD Serono and global collaborators shared promising results from Cohort B of the phase II trial of the WILLOW study.

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

Enpatoran, a TLR7/8 inhibitor, demonstrated clinically meaningful improvements in disease activity among patients with ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.